The mechanism of action of thyroid hormones

Annual Review of Physiology

Volumn 62, Issue , 2000, Pages 439-466

  Zhang, J ^a   Lazar, M A ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Chromatin; Hormone action; Repression; Thyroid hormone receptor; Transcription

Indexed keywords

CELL NUCLEUS RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; RETINOID X RECEPTOR; STEROID RECEPTOR; THYROID HORMONE; THYROID HORMONE RECEPTOR;

CHROMATIN STRUCTURE; DIMERIZATION; HORMONE ACTION; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; STOICHIOMETRY; TRANSCRIPTION REGULATION;

ANIMALS; GENE EXPRESSION REGULATION; HUMANS; RECEPTORS, THYROID HORMONE; THYROID HORMONES;

EID: 0033859843     PISSN: 00664278     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.physiol.62.1.439     Document Type: Review

References (220)

1. Thyroid hormone receptors: Multiple forms, multiple possibilities
2. The steroid and thyroid hormone receptor superfamily
3. The nuclear receptor superfamily: The second decade
4. The nuclear hormone receptor gene superfamily
5. Differential recognition of target genes by nuclear receptor monomers, dimers, and heterodimers
6. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D3 receptors
7. The orientation and spacing of core DNA-binding motifs dictate selective transcriptional responses to three nuclear receptors
8. A c-Erb-A binding site in rat growth hormone gene mediates trans- activation by thyroid hormone
9. Functional characterization of the rat growth hormone promoter elements required for induction by thyroid hormone with and without a co- transfected beta type thyroid hormone receptor
10. Retinoid X receptor interacts with nuclear receptors in retinoic acid, thyroid hormone and vitamin D3 signalling
11. Retinoid X receptor is an auxiliary protein for thyroid hormone and retinoic acid receptors
12. RXR beta: A coregulator that enhances binding of retinoic acid, thyroid hormone, and vitamin D receptors to their cognate response elements
13. H-2RIIBP (RXR beta) heterodimerization provides a mechanism for combinatorial diversity in the regulation of retinoic acid and thyroid hormone responsive genes
14. Purification, cloning, and RXR identity of the HeLa cell factor with which RAR or TR heterodimerizes to bind target sequences efficiently
15. Differential DNA binding by monomeric, homodimeric, and potentially heteromeric forms of the thyroid hormone receptor
16. RXR alpha, a promiscuous partner of retinoic acid and thyroid hormone receptors
17. Interactions among a subfamily of nuclear hormone receptors: The regulatory zipper model
18. Retinoic acid and thyroid hormone induce gene expression through a common responsive element
19. Determinants of target gene specificity for steroid/thyroid hormone receptors
20. Heterodimerization and deoxyribonucleic acid-binding properties of a retinoid X receptor-related factor
21. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA
22. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: How receptors discriminate between their response elements
23. Structural elements of an orphan nuclear receptor-DNA complex
24. Structural determinants of nuclear receptor assembly on DNA direct repeats
25. Specificity and mechanism of thyroid hormone induction from an octamer response element
26. Dimerization interfaces formed between the DNA binding domains determine the cooperative binding of RXR/RAR and RXR/TR heterodimers to DR5 and DR4 elements
27. The dimerization interfaces formed between the DNA binding domains of RXR, RAR and TR determine the binding specificity and polarity of the full- length receptors to direct repeats
28. Determinants for selective PAR and TR recognition of direct repeat HREs
29. Ordered binding of retinoic acid and retinoid-X receptors to asymmetric response elements involves determinants adjacent to the DNA- binding domain
30. Differential orientations of the DNA-binding domain and carboxy- terminal dimerization interface regulate binding site selection by nuclear receptor heterodimers
31. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation
32. A domain containing leucine-zipper-like motifs mediate novel in vivo interactions between the thyroid hormone and retinoic acid receptors
33. Positive and negative regulation of gene transcription by a retinoic acid-thyroid hormone receptor heterodimer
34. Mutations that alter ligand-induced switches and dimerization activities in the retinoid X receptor
35. Two distinct dimerization interfaces differentially modulate target gene specificity of nuclear hormone receptors
36. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha
37. Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region
38. Differential recognition of liganded and unliganded thyroid hormone receptor by retinoid X receptor regulates transcriptional repression
39. DNA-independent and DNA-dependent mechanisms regulate the differential heterodimerization of the isoforms of the thyroid hormone receptor with retinoid X receptor
40. The unique C-termini of the thyroid hormone receptor variant, c-ErbA alpha 2, and thyroid hormone receptor alpha 1 mediate different DNA- binding and heterodimerizafion properties
41. Dominant negative activity of an endogenous thyroid hormone receptor variant (alpha 2) is due to competition for binding sites on target genes
42. Thyroid hormone receptor variant alpha2. Role of the ninth heptad in DNA binding, heterodimerization with refinoid X receptors, and dominant negative activity
43. Functional regulation of thyroid hormone receptor variant TR alpha 2 by phosphorylation
44. Transactivation by thyroid hormone receptors: Functional parallels with steroid hormone receptors
45. Ligand-dependent and -independent transactivation by thyroid hormone receptor beta 2 is determined by the structure of the hormone response element
46. A unique role of the beta-2 thyroid hormone receptor isoform in negative regulation by thyroid hormone. Mapping of a novel amino-terminal domain important for ligand-independent activation
47. A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor alpha is essential for transcriptional activation and interaction with the general transcription factor TFIIB
48. The c-ErbA alpha-encoded thyroid hormone receptor is phosphorylated in its amino terminal domain by casein kinase II
49. Activation of protein kinase C or cAMP-dependent protein kinase increases phosphorylation of the c-ErbA-encoded thyroid hormone receptor and of the v-ErbA-encoded protein
50. Phosphorylation of the v-ErbA protein is required for its function as an oncogene
51. The c-ErbA gene encodes a thyroid hormone receptor
52. The c-ErbA protein is a high-affinity receptor for thyroid hormone
53. Phosphorylation of thyroid hormone receptors by protein kinase A regulates DNA recognition by specific inhibition of receptor monomer binding
54. A novel multifunctional motif in the amino-terminal A/B domain of T3Ralpha modulates DNA binding and receptor dimerization
55. Function of nuclear co-repressor protein on thyroid hormone response elements is regulated by the receptor A/B domain
56. Ligand-dependent cross-talk between steroid and thyroid hormone receptors - Evidence for common transcriptional coactivator(s)
57. Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor
58. Steroid hormone receptors compete for factors that mediate their enhancer function
59. Estrogen receptor-associated proteins: Possible mediators of hormone- induced transcription
60. A fraction enriched in a novel glucocorticoid receptor-interacting protein stimulates receptor-dependent transcription in vitro
61. Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
62. Analysis of the functional role of steroid receptor coactivator-1 in ligand-induced transactivation by thyroid hormone receptor
63. SRC-1 and GRIP1 coactivate transcription with hepatocyte nuclear factor 4
64. Mice deficient in the steroid receptor co-activator 1 (SRC-1) are resistant to thyroid hormone
65. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors
66. The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways
67. Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor2)
68. Mechanistic principles in NR box-dependent interaction between nuclear hormone receptors and the coactivator TIF2
69. An additional region of coactivator GRIP1 required for interaction with the hormone-binding domains of a subset of nuclear receptors
70. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors
71. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors
72. The transcriptional co-activator p/CIP binds CBP and mediates nuclear- receptor function
73. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300
74. Specific chromosomal aberrations and amplification of the AIB 1 nuclear receptor coactivator gene in pancreatic carcinomas
75. In breast cancer, amplification of the steroid receptor coactivator gene AIB1 is correlated with estrogen and progesterone receptor positivity
76. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer
77. TRAM-1, a novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1
78. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2
79. Thyroid hormone response element architecture affects corepressor release from thyroid hormone receptor dimers
80. Yeast hormone response element assays detect and characterize GRIP1 coactivator-dependent activation of transcription by thyroid and retinoid nuclear receptors
81. A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia
82. Acute mixed lineage leukemia with an inv(8)(p11q13) resulting in fusion of the genes for MOZ and TIF2
83. The translocation t(8;16)(p11↑3) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein
84. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors
85. Analysis of estrogen receptor transcriptional enhancement by a nuclear hormone receptor coactivator
86. Ligand-dependent, transcriptionally productive association of the amino- and carboxyl-terminal regions of a steroid hormone nuclear receptor
87. Steroid receptor coactivator-1 is a histone acetyltransferase
88. Histone-like TAFs within the PCAF histone acetylase complex
89. The histone acetylase PCAF is a nuclear receptor coactivator
90. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A
91. A natural transactivation mutation in the thyroid hormone beta receptor: Impaired interaction with putative transcriptional mediators
92. A role for helix 3 of the TRbeta ligand-binding domain in coactivator recruitment identified by characterization of a third cluster of mutations in resistance to thyroid hormone
93. Resistance to thyroid hormone
94. Lack of coactivator interaction can be a mechanism for dominant negative activity by mutant thyroid hormone receptors
95. Genetic and clinical features of 42 kindreds with resistance to thyroid hormone. The National Institutes of Health Prospective Study
96. Hormone-dependent coactivator binding re, a hydrophobic cleft on nuclear receptors
97. A structural role for hormone in the thyroid hormone receptor
98. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300
99. Nuclear protein CBP is a coactivator for the transcription factor CREB
100. Phosphorylated CREB binds specifically to the nuclear protein CBP
101. E1A-associated p300 and CREB-associated CBP belong to a conserved family of coactivators
102. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP
103. Role of CBP/P300 in nuclear receptor signalling
104. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors
105. P300 is a component of an estrogen receptor coactivator complex
106. Nuclear integration of JAK/STAT and Ras/AP-1 signalling by CBP and p300
107. Recruitment of p300/CBP in p53-dependent signal pathways
108. Cooperation of Stat2 and p300/CBP in signalling induced by interferon- alpha
109. Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator
110. Interaction and functional collaboration of p300 and C/EBPbeta
111. The transcriptional integrator CREB-binding protein mediates positive cross talk between nuclear hormone receptors and the hematopoietic bZip protein p45/NF-E2
112. Transcription: A growing coactivator network
113. Transcription factor-specific requirements for coactivators and their acetyltransferase functions
114. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex
115. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system
116. The transcriptional cofactor complex CRSP is required for activity of the enhancer-binding protein Sp1
117. A novel human SRB/ MED-containing cofactor complex, SMCC, involved in transcription regulation
118. NAT, a human complex containing Srb polypeptides that functions as a negative regulator of activated transcription
119. A thyroid hormone receptor coactivator negatively regulated by the retinoblastoma protein
120. Isolation and characterization of a novel ligand-dependent thyroid hormone receptor-coactivating protein
121. A signature motif in transcriptional co-activators mediates binding to nuclear receptors
122. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation
123. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
124. The v-ErbA oncogene is a thyroid hormone receptor antagonist
125. Requirement for the C-terminal domain of the v-ErbA oncogene protein for biological function and transcriptional repression
126. V-ErbA oncogene activation entails the loss of hormone-dependent regulator activity of c-ErbA
127. Thyroid hormone receptor/and v-ErbA: A single amino acid difference in the C-terminal region influences dominant negative activity and receptor dimer formation
128. A transferable silencing domain is present in the thyroid hormone receptor, in the v-ErbA oncogene product and in the retinoic acid receptor
129. Unliganded thyroid hormone receptor inhibits formation of a functional preinitiation complex: Implications for active repression
130. Unliganded thyroid hormone receptor alpha can target TATA-binding protein for transcriptional repression
131. Interaction of human thyroid hormone receptor beta with transcription factor TFIIB may mediate target gene derepression and activation by thyroid hormone
132. Functional evidence for ligand-dependent disassociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor
133. The ligand-binding domains of the thyroid hormone/retinoid receptor gene sub-family function in vivo to mediate heterodimerization, gene silencing, and transactivation
134. Transcriptional silencing by unliganded thyroid hormone receptor beta requires a soluble corepressor that interacts with the ligand-binding domain of the receptor
135. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor
136. Isolation of proteins that interact specifically with the retinoid X receptor: Two novel orphan receptors
137. A transcrip, tional co-repressor that interacts with nuclear hormone receptors
138. Unique forms of human and mouse nuclear receptor corepressor SMRT
139. Identification of TRACs (T3 receptor-associating cofactors), a family of cofactors that associate with, and modulate the activity of, nuclear hormone receptors
140. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase
141. Characterization of receptor interaction and transcriptional repression by the corepressor SMRT
142. SMRT isoforms mediate repression and anti-repression of nuclear receptor heterodimers
143. A nuclear hormone receptor corepressor mediates transcriptional silencing by receptors with distinct repression domains
144. Identification and characterization of a novel corepressor interaction region in RVR and Rev-ErbA alpha
145. Transcriptional repression by COUP-TF II is dependent on the C- terminal domain and involves the N-CoR variant, RIP13delta1
146. Gene silencing by chicken ovalbumin upstream promoter-transcription factor I (COUP-TFI) is mediated by transcriptional corepressors, nuclear receptor-corepressor (N-CoR) and silencing mediator for retinoic acid receptor and thyroid hormone receptor (SMRT)
147. The BCL-6 POZ domain and other POZ domains interact with the co- repressors N-CoR and SMRT
148. SMRT corepressor interacts with PLZF and with the PML-retinoic acid receptor alpha (RAR-alpha) and PLZF-RARalpha oncoproteins associated with acute promyelocytic leukemia
149. Polarity-specific activities of retinoic acid receptors determined by a co-repressor
150. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia
151. Thyroid abnormalities and hepatocellular carcinoma in mice transgenic for v-ErbA
152. A single point mutation in erbA restores the erythroid transforming potential of a mutant avian erythroblastosis vires (AEV) defective in both erbA and erbB oncogenes
153. Identification of a domain required for oncogenic activity and transcriptional suppression by v-ErbA and thyroid-hormone receptor alpha
154. Transcriptional repression by the SMRT-mSin3 corepressor: Multiple interactions, multiple mechanisms, and a potential role for TFIIB
155. Two separate NCoR (nuclear receptor corepressor) interaction domains mediate corepressor action on thyroid hormone response elements
156. Two receptor interacting domains in the nuclear hormone receptor corepressor RIP13/N-CoR
157. Stoichiometric and steric principles governing repression by nuclear hormone receptors
158. Transcriptional regulatory patterns of the myelin basic protein and malic enzyme genes by the thyroid hormone receptors alphal and betal
159. The thyroid hormone receptor variant alpha2 is a weak antagonist because it is deficient in interactions with nuclear receptor corepressors
160. Two silencing sub-domains of v-ErbA synergize with each other, but not with RXR
161. Cloning and characterization of a corepressor and potential component of the nuclear hormone receptor repression complex
162. A nuclear hormone receptor-associated protein that inhibits transactivation by the thyroid hormone and retinoic acid receptors
163. The monomer-binding orphan receptor Rev-Erb represses transcription as a dimer on a novel direct repeat
164. Proteasomal regulation of nuclear receptor corepressor-mediated repression
165. PHYL acts to down-regulate TTK88, a transcriptional repressor of neuronal cell fates, by a SINA-dependent mechanism
166. Photoreceptor cell differentiation requires regulated proteolysis of the transcriptional repressor Tramtrack
167. Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression
168. Histone deacetylases and SAP18, a novel polypeptide, are components of a human Sin3 complex
169. Histone deacetylase activity of Rpd3 is important for transcriptional repression in vivo
170. SAP30, a novel protein conserved between human and yeast, is a component of a histone deacetylase complex
171. Role for N-CoR and histone deacetylase in Sin3-mediated transcriptional repression
172. Histone deacetylase activity is required for full transcriptional repression by mSin3A
173. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression
174. SAP30, a component of the mSin3 corepressor complex involved in N-CoR- mediated repression by specific transcription factors
175. What's up and down with histone deacetylation and transcription?
176. The corepressor N-CoR and its variants RIP13a and RIP13Deltal directly interact with the basal transcription factors TFIIB, TAFII32 and TAFII70
177. Distinct requirements for chromatin assembly in transcriptional repression by thyroid hormone receptor and histone deacetylase
178. Nuclear corepressors enhance the dominant negative activity of mutant receptors that cause resistance to thyroid hormone
179. Thyroid hormone resistance syndrome manifests as an aberrant interaction between mutant T3 receptors and transcriptional corepressors
180. Requirement of corepressor binding of thyroid hormone receptor mutants for dominant negative inhibition
181. Thyroid hormone resistance syndrome: Correlation of dominant negative activity and location of mutations
182. Thyroid hormone receptor mutants that cause resistance to thyroid hormone. Evidence for receptor competition for DNA sequences in target genes
183. Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML- and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia
184. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co- repressors determine differential responses to RA in APL
185. Acute promyelocytic leukemia: Relieving repression induces remission
186. Role of the histone deacetylase complex in acute promyelocytic leukaemia
187. Acute promyelocytic leukemia, histone deacetylase, and response to retinoids
188. Aberrant recruitment of the nuclear receptor corepressor-histone deacetylase complex by the acute myeloid leukemia fusion partner ETO
189. ETO, a target of t(8;21) in acute leukemia, interacts with the N-CoR and mSin3 corepressors
190. ETO, fusion partner in t(8;21) acute myeloid leukemia, represses transcription by interaction with the human N-CoR/mSin3/HDAC1 complex
191. NURD, a novel complex with both ATP-dependent chromatin-remodeling and histone deacetylase activities
192. The dermatomyositis-specific autoantigen Mi2 is a component of a complex containing histone deacetylase and nucleosome remodeling activities
193. A multiple subunit Mi-2 histone deacetylase from Xenopus laevis cofractionates with an associated Snf2 superfamily ATPase
194. Role of nucleosome remodeling factor NURF in transcriptional activation of chromatin
195. Drosophila NURF-55, a WD repeat protein involved in histone metabolism
196. Role of histone tails in nucleosome remodeling by Drosophila NURF
197. ISWI, a member of the SWI2/ SNF2 ATPase family, encodes the 140 kDa subunit of the nucleosome remodeling factor
198. Conformational adaptation of agonists to the human nuclear receptor RAR gamma
199. Crystal structure of the RAR-gamma ligand-binding domain bound to all- trans retinoic acid
200. Crystal structure of the ligand binding domain of the human nuclear receptor PPAR gamma
201. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma
202. Molecular basis of agonism and antagonism in the oestrogen receptor
203. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen
204. Atomic structure of progesterone complexed with its receptor
205. Molecular and structural biology of thyroid hormone receptors
206. X-ray crystallographic and functional studies of thyroid hormone receptor
207. Differential expression of alpha and beta thyroid hormone receptor genes in rat brain and pituitary
208. Spatial and temporal expression of alpha- and beta-thyroid hormone receptor mRNAs, including the beta 2-subtype, in the developing mammalian nervous system
209. Contrasting developmental and tissue-specific expression of alpha and beta thyroid hormone receptor genes
210. Distinct functions for thyroid hormone receptors alpha and beta in brain development indicated by differential expression of receptor genes
211. Relationship of c-ErbA mRNA content to tissue trilo-dothyronine nuclear binding capacity and function in developing and adult rats
212. Immunofluorescence localization of thyroid hormone receptor protein beta 1 and variant alpha 2 in selected tissues: Cerebellar Purkinje cells as a model for beta 1 receptor-mediated developmental effects of thyroid hormone in brain
213. Abnormal heart rate and body temperature in mice lacking thyroid hormone receptor alpha 1
214. The T3R alpha gene encoding a thyroid hormone receptor is essential for post-natal development and thyroid hormone production
215. Thyroid hormone receptor beta is essential for development of auditory function
216. Recessive resistance to thyroid hormone in mice lacking thyroid hormone receptor beta: Evidence for tissue-specific modulation of receptor function
217. Different functions for the thyroid hormone receptors TRalpha and TRbeta in the control of thyroid hormone production and post-natal development